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Background: Hepatic resection of liver metastases of non-colorectal, non-neuroendocrine, and non-sarcoma
(NCNNNS) primary malignancies seems to improve survival in selected patients. The aims of the current review were
to describe long-term results of surgery and to evaluate prognostic factors for survival in patients who underwent
resection of NCNNNS liver metastases.
Methods: We identified 30 full texts (25 single-center and 5 multicenter studies) published after year 1995 and published
in English with a total of 3849 patients. For NCNNNS liver metastases, 83.4 % of these subjects were resected.
Results: No prior systematic reviews or meta-analyses on this topic were identified. All studies were case series
without matching control groups. The most common primary sites were breast (23.8 %), genito-urinary (21.8 %),
and gastrointestinal tract (19.8 %). The median 5- and 10-year overall survival were 32.3 % (range 19–42 %) and
24 % (indicated only in two studies, range 23–25 %), respectively, with 71 % of R0 resections.
Conclusions: There is evidence suggesting that surgery of NCNNNS metastases is safe, feasible, and effective if
treatment is part of a multidisciplinary approach and if indication is based on the prognostic factors underlined in
literature analysis.
Keywords: Liver metastases, Non-colorectal, Non-neuroendocrine, Non-sarcoma, Liver resection, Prognostic factorsReview
Due to its filter role in the portal circulation, the liver is
often the first organ involved in metastatic dissemination
of gastrointestinal neoplasms. Hepatic resection is an
established and recognized procedure for the treatment
of colorectal liver metastases, and it is associated with
higher survival rates than more conservative therapies.
In fact, patients who undergo complete resections (R0)
have a 5-year survival rate of approximately 40 % and a
10-year overall survival rate of 25 % [1–10]. The role of
surgery for metastases from neuroendocrine neoplasms
on long-term outcome is also well-documented [11, 12].
Recently, some authors analyzing liver metastases from
sarcomas reported similar results to colorectal and* Correspondence: fabio.uggeri@unimib.it
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creativecommons.org/publicdomain/zero/1.0/neuroendocrine cancer with a 5-year survival ranging
from 26 to 36 % [13, 14]. The increasing attention has
led to a better standard of care. A multidisciplinary ap-
proach, surgical techniques, perioperative management,
and technological advances have all contributed to the
improvement of long-term survival after liver resections
over the last two decades.
On the other hand, several other primary sites develop
metastases in hepatic parenchyma. With regard to this third
group of cancers (non-colorectal, non-neuroendocrine, and
non-sarcomas (NCNNNS)), there is a paucity of data in
medical literature. In fact, studies either had small number
of patients likely due to the relative rarity and the lack of
centralization in high volume centers, or they investigated
diseases from primary tumors with different prognoses, in-
cluding metastasis from cancer of the colorectum, neuroen-
docrine tissues, and sarcoma.rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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term results of surgery and identify prognostic factors
for survival in a heterogeneous group of liver metastases
from NCNNNS primaries malignancies.
Material and methods
Literature search strategy
The original published studies were searched via PubMed
and Medline databases, between 1995 and 2014. The fol-
lowing keywords were utilized: “liver” and “metastases”,
“non-colorectal”, “non-neuroendocrine”, “non-sarcoma”,
“hepatectomy” (or “resection”), and “prognostic factors”.
More than 5000 references were identified. The reference
lists of all retrieved articles were reviewed to further iden-
tify potentially relevant studies.
The purpose of data extraction has been to identify
those items in which the percentage of patients who
were resected for NCNNNS liver metastases was higher
than 50 %.
Selection criteria
Observational clinical studies that used hepatic resection
as a therapeutic option for NCNNNS malignancies were
identified for inclusion. All relevant prospective and retro-
spective series were also included. Specific inclusion cri-
teria were studies published after the year 1995, human
articles, and papers published in the English language.
Abstracts, reviews, letters, editorials, case reports, expert
opinions, and articles contain short reviews were excluded.
The final result is the analysis of 30 full texts: 25 single-
center studies and 5 multicenter studies [15–44].
Data extraction
Two reviewers independently appraised each article
using similar protocols. Data extracted were: method-
ology, patient number and characteristics, outcomes,
length of follow-up, overall survival or progression-free
survival, mortality, morbidity, and prognostic factors.
Median values and percentages were determined after
tabulation of the results from the included studies. All
the studies included in the present review aimed to dem-
onstrate the efficacy of hepatic resection for liver metas-
tases, although a minority evaluated also other
concomitant ablative techniques.
Results
The 30 studies included a total of 3849 patients (Fig. 1).
All studies were case series without matching control
groups: 11 studies described more than 100 patients [16,
24, 26, 29, 34–37, 41, 43, 44], 6 studies between 50 and
100 patients [15, 17, 31, 38, 39, 42], and 13 studies less
than 50 patients [18–23, 25, 27, 28, 30, 32, 33, 40]. No
prior systematic reviews or meta-analyses on this topic
were identified. The largest series was published byAdam et al. in 2006 [37] including 1452 patients who
underwent surgical procedures. In 22 studies, patients can-
didates to hepatic resection of liver metastases (LM) were
the target population, but subjects undergoing alternative,
additional surgical procedures (mainly radiofrequency abla-
tion or cryoablation in addition to partial hepatectomy) or
palliative treatment was included for the purpose of com-
parison [15, 20–31, 34–37, 39–43]. Study objectives and in-
clusion criteria were clearly described in all the studies.
Twenty-eight studies reported overall survival results
(Table 1), which were unclear in one article [23].
Twenty-one studies reported data on progression-free
survival [16–20, 24, 25, 29, 31–33, 35–44]. Each article
reported length of follow-up of at least 5 years. The 5-
and 10-year overall survival ranges were 19–42 % and
23–25 %, respectively, with a mean 5-year overall sur-
vival of 32.3 % (Table 1).
Figures 1 and 2 present the results of the primary sites
and systemic spread of metastases. The most common
primary sites were breast (23.8 %), genito-urinary
(21.8 %), and gastrointestinal tract (19.8 %). Sixteen
studies included patients with extrahepatic metastases
[16–18, 24, 25, 27–31, 33, 36, 37, 42–44], whereas four-
teen studies included patients with isolated liver disease
only, or the presence of extrahepatic metastases at the
time of hepatic resection was not specified [15, 19–23,
25, 26, 32, 34, 38–41]. The presence of extrahepatic dis-
ease wildly ranged between 0 and 53.1 % because several
authors considered it an exclusion criterion for surgery,
while others did not deem extrahepatic disease a contra-
indication or a negative prognostic factor. Therefore,
liver resection was performed with the intent to achieve
a radical resection (R0). Metastases affected two hepatic
lobes in 0–37.5 % of patients. The presence of bilobar
metastases or extrahepatic disease may not be consid-
ered as a contraindication for surgery [16, 17, 29–31, 33,
34, 38, 40, 42, 44]; 18 % of authors resected bilobar dis-
eases, otherwise considering this criteria a prognostic
factor that impact prognosis. Figure 3 also shows the re-
sults regarding the status of the surgical margin: al-
though an R0 resection is always the primary objective
of the surgeon, it is obtained in 2736 of the 3849 pa-
tients, although it is specified only in 21 studies.
A detailed evaluation of significant and non-significant
prognostic factors for overall survival and progression-free
survival is presented in Table 2. By the univariate analysis,
the most common factors (reported in ≥3 studies) associ-
ated with poor survival analysis were the following: age,
synchronous metastatic disease, site of the primary tumor,
presence of symptoms, type and extension of hepatec-
tomy, macroscopic (R2) residual disease and distance of
free-surgical margin, adjuvant treatment, presence of ex-
trahepatic disease, number of hepatic lesions and the size
of the greatest one, and bilobar disease.
Fig. 1 Total number of patients and origins of metastases
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tors as follows:
– primary site and histological subtype (22 articles,
Table 2); liver metastases from breast kidney, uterus,
ovary, testicle, ampulla of Vater, and adrenal gland
cancer had a 5-year overall survival greater than
30 %, while metastases from gastric and duodenum
cancer had a survival between 30 and 15 %; liver
metastases from pancreas, anus, esophagus, cardia,
and lung cancers had a 5-year overall survival less
than 15 % [37, 43].
– size and number of metastases (11 articles, Table 2);
the prognosis worsened especially when the number
of metastases was higher than 3–4 and the size
greater than 5–6 cm.
– surgical margin status (10 articles, Table 2); to
perform surgery with curative intent, it is necessary
to accomplish disease-free resection margins (R0).
Nevertheless, R0 resection was reported with a
range between 55.9 [19] and 100 % of cases [28, 30,
32], showing that a complete excision of the lesion is
not always achievable suggesting that the margin of
resection could be an important prognostic factor,
on overall survival.
– type of the intervention performed (5 articles,
Table 2); the extent of hepatectomy was also an
independent negative prognostic factor, possibly
reflecting the magnitude of tumor burden [37].
– time of metastasis appearance (6 articles, Table 2).
Despite the presence of synchronous metastases
might represent the disease aggressiveness, the5-year overall survival in patients with metachro-
nous disease or synchronous disease were 31–37 %
and 31–36 %, respectively [16, 37].
Discussion
The role of surgery in the management of liver metastases
from colorectum (CR) or neuroendocrine tumors has been
well described in the literature; several studies have focused
their attention on the surgical indications of these patients
and the respective outcomes, showing the need for an ag-
gressive surgical therapy. In particular, surgical treatment of
metastatic CR cancer has improved long-term outcome. A
5-year survival rate was 25 % in the 80s, progressively in-
creased up to 47 % in 2008 [7, 45–51]. In contrast, the
treatment of NCNNNS liver metastases does not have a
clearly defined role, mostly because of discrepant character-
istics of patients, difficulty in their selection, and lack of
high volume series.
The aim of this review is to help shedding light on this
controversial topic not adequately outlined so far.
Several multicenter studies and reviews report a survival
rate ranging from 27.9 to 49.3 % in patients with metastases
from non-CR cancer, depending on the tumor histology [5].
Although the set of “non-CR metastases” is extremely het-
erogeneous, there is a general agreement on the surgical
treatment of some homogeneous groups of tumors such as
metastases from neuroendocrine tumors and sarcoma. In
these cases, the resection has been proved safe and able to
prolong survival compared to non-invasive treatments,
obtaining an overall survival rate at 5-year of 20–33 % and
of 46–86 % for sarcoma and neuroendocrine tissues, re-
spectively [11–14, 24, 52].
Table 1 Overall and disease-free survival
First author Overall survival Disease-free survival
Median (months) 1 year (%) 2 years (%) 3 years (%) 5 years (%) 10 years (%) Median (months) 1 year (%) 2 years (%) 3 years (%) 5 years (%) 10 years (%)
Harrison [38] 32 80 – 45 37 – – – – – – 18.7
Lindell [27] 32 75 – – 36 25 – – – – – –
Elias [24] – – – – 36 – – – – – 28 –
Berney [19] 19 61 43 – 27 – 36a – – – – –
Hamy [22] 19.6 54 ± 8 42 ± 8 – 27 ± 8 – – – – – – –
Benevento [25] 38 ± 11 54 42 – 21 – – – – – – –
Hemming [40] 46 85 – 55 45 – 28a – – – – –
Takada [23] 0–53 – – – – – – – – – – –
Van Ruth [18] 21 – – – 35 – 12 – – – 20 –
Laurent [30] – 81 – 40 35 – – – – – – –
Goering [20] 45 82 – 55 39 – – 43 – 21 – –
Karavias [28] – – – 78 – – – – – – – –
Torras [33] – 86 48 – – – 53 ± 38 50 25 – – –
Yedibela [16] 23 – 49 – 26 – 25 – – – – –
Weitz [35] 42 – – 57 – – 17 – – 30 – –
Cordera [31] 28.8 81.1 – 43 30.2 – 13.2 64.7 – – 15.8 –
Earle [17] 36 88.5 – 49.1 34.9 – 21.5 – – – – –
Adam [37] 35 – – – 36 23 13 – – – 21 15
Verhoef [21] 37 – – – 42 – – – – – – –
Lendoire [34] 27 67 – 34 19 – – – – – – –
O’Rourke [29] 42 – – 56.1 38.5 – 18 – – 37.2 26.5 –
Pais Costa [32] – – – 50 – – – – – 40 – –
Ercolani [41] 35.5 ± 6.4 83.6 – 56.5 40 – 26.6 ± 4.1 75 – 44 30 –
Duan [26] 38.8 ± 26.7 84.8 – 44.7 29.5 – – – – – – –
Bresadola [39] 20 71.9 – 42.8 28.9 – 19–44 68–85 – 29–63 19–52 –
Marudanayagam [42] 19 72.9 – 47.9 25.6 – 19 – – – – –
Treska [15] – 88.6 – 72.5 36.9 – – – – – – –
Groeschl [36] 49 73 – 50 31 – 23 – – – – –
Slotta [43] 20.5 66 – 43 30 – – – – – 39 –
Takemura [44] 41.8 83.9 – 55.4 41 – 10 43.7 – 21.1 18.1 –
Range 0–53 19–42 23–25 10–53 15.8–52 15–18.7














Fig. 2 Metastatic involvement
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technological and cultural evolutions in surgery has im-
proved the prognosis in patients treated from 1978 to
2014, especially in terms of 5-year overall survival. The
most recent data on the treatment of metastatic non-CR
cancer are comparable to those reported in the literature
in studies on the treatment of metastatic CR cancer
dated 15–20 years ago [53–55].
Beyond the heterogeneity in terms of histology of the
primary disease and the stage of cancer, the improve-
ment in the survival rates of patients undergoing surgeryFig. 3 Resection marginstrengthens and demonstrates the utility of resection
with a 19–42 % 5-year survival rates.
The theory defining tumor spreading to the liver as a
“systemic” and not a “regional” disease is obsolete and
justifies why liver metastases were not surgically re-
moved until some decades ago. Despite the presence of
metastases representing an advance disease and that
hematogenous dissemination may be a contraindication
for surgery, the most recent results suggest that surgery,
combined by chemotherapy, is useful in this type of
systemic diseases by improving overall.
Table 2 Prognostic factors
Prognostic factor Variables that influence overall survival Variables that influence progression-free survival
Sex 39 35
Preoperative treatment of liver 15
Metastatic situation: synchronous/metachronous 17, 23, 27, 34, 38 44
Primary site and histological subtype 15–26, 33, 34, 37–41, 43 31, 35
Symptomatic at the time of resection 41a
Hepatic involvement 25, 26
Type of the intervention performed 17, 37, 39–41
Macroscopically incomplete resection (R2) 17, 19, 38, 40 29
Surgical margin status 16, 17, 19, 32, 34, 37, 38, 40, 42 35
Adjuvant treatment 15, 17, 18, 20, 21, 24–26, 37 44
Presence of extrahepatic disease 15, 16, 20, 27, 28, 30, 37
Surgery timing 19, 22, 26, 31 31
Postoperative complications 17, 44 44
Number of metastases 17, 19, 26, 27, 33, 39, 44 44
Size of metastases 26, 29, 36, 41, 42 29, 44
Presence of vascular invasion 36
Lymph node metastases 29, 36, 39 29
Disease-free survival 26, 30, 37, 38, 41 17, 31, 35, 44
Blood transfusion 44 44
aSymptoms within 1 year
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debated topic until about 15 years ago, when improved
survival was reported among patients operated on for
hepatic metastases from testicular, kidney, and breast
cancers [19, 24].
The surgical approach to non-CR liver metastases is
essentially based on two fundamental issues that have
become increasingly important in the last two decades:
– Hepatic resection has become safer thanks to
improved surgical techniques and an accurate
pre-and intraoperative imaging allowing
parenchyma spearing.
– The complementary role of new and effective
chemotherapy agents and surgery for some
non-CR tumors
Therefore, it appears that the role of surgery in the
treatment of liver metastases may be a relevant hope for
patients when they meet the criteria of resectability, re-
gardless the number of metastases; further efforts should
be pursued to better evaluate its clinical impact and
standardize management protocols.
Regarding surgical margin, it is considered safe when
>0.5–1 cm since shorter margins are associated with higher
rates of recurrence. However, as already shown for colorec-
tal cancer, the overall survival rate seems to be not signifi-
cantly influenced by the margin width but more by thepresence of residual disease (R1-R2 versus R0) [17, 19, 34,
37, 38, 40, 42]. As such, it might be that 1 mm is sufficient
to improve survival. In addition, the more patients with ad-
vanced diseases (multiple metastases, bilobar, or large) are
resected, the more clearly liver parenchyma must be pre-
served, obtaining less wide margins. Debulking surgery is a
fairly debated topic, because up to date, it has not been
demonstrated to impact survival results [14, 56, 57], unless
an R0 resection is unachievable with adjuvant/neoadjuvant
[13] and medical therapy has failed.
Contraindications to debulking surgery seem to apply
in particular to rapidly progressive metastatic disease
not controlled by systemic treatments and to synchron-
ous liver metastases, except for breast [37] and genito-
urinary tract [43] neoplasms because the efficacy of
medical treatments allow to improve survival and to
stretch the limit of surgery.
Up-front hepatic resection seems contraindicated in
patients with major comorbidities or for tumors with ad-
vanced invasion of major vessels and in those with an
expected residual liver volume less than 30–40 % after
resection. In the latest cases, neoadjuvant chemotherapy
or other cytoreductive approaches may allow delayed reex-
amination and new judgment of operability and resectabil-
ity. However, in some chemoresistant tumors (melanomas,
kidney), surgery should be considered, when feasible, as the
only possible therapy with curative intent and should not
be delayed.
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relative contraindication to liver surgery.
An half of the studies analyzed deem the presence of an
extrahepatic an absolute contraindication to surgical re-
section, while the remnant studies push the limit of surgi-
cal approach with the aim to obtain an R0 resection.
In our univariate analysis, the most common prognos-
tic factors related to the 5-year overall survival rate was
the site of the primitive tumor and the histological sub-
type. In particular, the worse prognosis was for hepatic
metastases from gastrointestinal tumors, except for well-
selected patients with metachronous metastases from
gastric cancer.
The low rate of complication after elective liver sur-
gery and the survival benefit observed in association
with hepatectomy with more than one third of patients
alive at 5 years and subsequently a quarter to 10 years
support the inclusion of surgery in a multidisciplinary
set of care for these patients.
Conclusions
Liver resection for NCNNNS metastases seems to be
safe and feasible. Long-term outcome is deeply affected
by some clinical and pathological features, such as the
histology of the primary tumor. Statistical models based
on correct patient prognostic factors can help to predict
long-term survival.
Currently, there is evidence that the surgery of
NCNNNS metastases is effective if the indication is based
on the evaluation of precise risk factors and if surgery is
associated with complementary therapies. The major ben-
efits are accomplished for genito-urinary and breast can-
cer, for size of mestastases less than 5 cm, a curative
resection is achieved and when the appearance of hepatic
lesions is longer than 12 months from primary tumors.
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